NI201500179A - Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina - Google Patents
Compuestos heteroaromáticos y su uso como ligandos d1 de dopaminaInfo
- Publication number
- NI201500179A NI201500179A NI201500179A NI201500179A NI201500179A NI 201500179 A NI201500179 A NI 201500179A NI 201500179 A NI201500179 A NI 201500179A NI 201500179 A NI201500179 A NI 201500179A NI 201500179 A NI201500179 A NI 201500179A
- Authority
- NI
- Nicaragua
- Prior art keywords
- disorder
- cognitive
- compounds
- schizophrenia
- post
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención proporciona, en parte, los compuestos de Fórmula (I) y las sales farmacéuticamente aceptables de los mismos; procesos para la preparación de; intermediarios utilizados en la preparación de; y composiciones que contienen los compuestos o sales, y su usos para los trastornos mediados por D1 (o asociados con D1) que incluyen, por ejemplo, la esquizofrenia (por ejemplo, sus síntomas cognitivos y negativos), discapacidad cognitiva (por ejemplo, discapacidad cognitiva asociada con la esquizofrenia, AD , PD, o terapia de farmacoterapia), ADHD, impulsividad, juego compulsivo, comer en exceso, trastorno del espectro de autismo, MCI, declive cognitivo relacionado con la edad, demencia, RLS, enfermedad de Parkinson, corea de Huntington, ansiedad, depresión, MDD, TRD, trastorno bipolar, apatía crónica, anhedonia, fátiga crónica, trastornos por estrés post-traumático, trastorno afectivo estacional, trastorno de ansiedad social, depresión post-parto, síndrome de serotonina, dependencia de abuso de sustancias y fármacos, recaída por abuso de fármacos, síndrome de Tourette, disquinesia tardía, somnolencia, somnolencia diurna excesiva, caquexia, falta de atención, disfunción sexual, migraña, SLE, hiperglicemia, aterosclerosis, dislipidemia, obesidad, , diabetes, sepsis, necrosis tubular post-isquémica, falla renal, hiponatremia, edema resistente, narcolepsia, hipertensión, falla cardiaca congestiva, hipotonía ocular postoperativa, trastornos del sueño, y dolor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361840144P | 2013-06-27 | 2013-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201500179A true NI201500179A (es) | 2016-02-11 |
Family
ID=51205521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201500179A NI201500179A (es) | 2013-06-27 | 2015-12-22 | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina |
Country Status (42)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3323821A1 (en) | 2012-11-08 | 2018-05-23 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
WO2014207601A1 (en) | 2013-06-27 | 2014-12-31 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
BR112016023740A2 (pt) | 2014-04-25 | 2017-08-15 | Pfizer | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 |
CA2946471C (en) | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands |
EP3137469B1 (en) | 2014-04-28 | 2019-10-09 | Pfizer Inc | Heterocyclic compounds and their use as dopamine d1 ligands |
EP3137454A1 (en) | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
CN111153859B (zh) * | 2015-04-15 | 2021-09-03 | 江苏恩华药业股份有限公司 | 哒嗪酮类衍生物及其应用 |
BR112018007395A2 (pt) | 2015-10-14 | 2018-10-23 | Bristol-Myers Squibb Company | 2,4-di-hidróxi-nicotinamidas como agonistas de apj |
ES2820823T3 (es) | 2015-12-18 | 2021-04-22 | Janssen Pharmaceutica Nv | Ligandos PET mGluR2/3 radiomarcados |
AU2016374571B2 (en) | 2015-12-18 | 2021-05-06 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
ES2837018T3 (es) * | 2016-01-15 | 2021-06-29 | Pfizer | Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina |
BR112018068341A2 (pt) | 2016-03-24 | 2019-01-15 | Bristol-Myers Squibb Company | 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj |
CN108884055B (zh) | 2016-03-30 | 2022-07-12 | 石原产业株式会社 | 哒嗪酮系化合物或其盐、以及含有它们的除草剂 |
WO2018157843A1 (zh) * | 2017-03-02 | 2018-09-07 | 中国科学院上海药物研究所 | 2-(取代苯杂基)芳香甲酸类fto抑制剂,其制备方法及其应用 |
JP2023522949A (ja) * | 2020-04-23 | 2023-06-01 | オプナ バイオ ソシエテ アノニム | Cd73調節のための化合物及び方法並びにそれらの表示 |
EP4441039A1 (en) | 2021-12-03 | 2024-10-09 | Teva Czech Industries s.r.o | Solid state forms of tavapadon and processes for preparation thereof |
WO2023143321A1 (zh) * | 2022-01-29 | 2023-08-03 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5025142B1 (es) | 1969-07-30 | 1975-08-21 | ||
JPS5039272B1 (es) | 1970-07-14 | 1975-12-16 | ||
JPS5025142A (es) | 1973-07-06 | 1975-03-17 | ||
JPS5039272A (es) | 1973-08-10 | 1975-04-11 | ||
JPS5516432B2 (es) | 1974-05-28 | 1980-05-01 | ||
JPS51113899A (en) | 1975-03-27 | 1976-10-07 | Yoshitomi Pharmaceut Ind Ltd | Method for preparing novel tetrazole derivatives |
JPS522031A (en) | 1975-06-24 | 1977-01-08 | Japan Niyuupureito Hokushiyou | Sunshade device |
DE2861615D1 (en) | 1978-01-02 | 1982-03-11 | Ciba Geigy Ag | Phenoxy-alkyl oxazolines, their preparation, compositions containing them and their application as herbicides |
EP0101662A3 (de) | 1982-06-25 | 1985-12-04 | Ciba-Geigy Ag | Benzoylparabansäuren |
US4550108A (en) | 1983-08-17 | 1985-10-29 | Ciba Geigy Corporation | 1,3,5-Oxadiazine-2,4-diones and pesticidal use |
US4723015A (en) | 1983-10-17 | 1988-02-02 | Ciba-Geigy Corporation | Certain insecticidal N-2-pyridyloxyphenylbenzimidates |
IL73611A0 (en) | 1983-12-06 | 1985-02-28 | Nippon Soda Co | 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides |
JPS61275271A (ja) | 1985-05-30 | 1986-12-05 | Nippon Soda Co Ltd | 1,2,4−オキサ(チア)ジアゾリン誘導体、その製造方法,殺虫剤及び農園芸用殺菌剤 |
DE3545569A1 (de) | 1985-12-21 | 1987-06-25 | Hoechst Ag | Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel |
DE3545786A1 (de) | 1985-12-21 | 1987-06-25 | Schering Ag | Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung |
DE3631511A1 (de) | 1986-09-12 | 1988-03-24 | Schering Ag | 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel |
EP0296518A1 (de) | 1987-06-22 | 1988-12-28 | Ciba-Geigy Ag | Neue Phenylether-derivate als Mikrobizide, Verfahren zu deren Herstellung und deren Verwendung |
DE3826855A1 (de) * | 1988-08-06 | 1990-02-15 | Cassella Ag | 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung |
JPH0259574A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ピラジノン誘導体又はその塩類 |
JPH0259573A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | 2(1h)−ピリミジノン誘導体又はその塩類 |
US5066667A (en) | 1989-06-26 | 1991-11-19 | Ciba-Geigy Corporation | Thioxotetrazolines and insecticidal use thereof |
DE69104071T2 (de) | 1990-01-18 | 1995-05-11 | Nissan Chemical Ind Ltd | Uracilderivate und Pestizide, die diese als wirksame Stoffe enthalten. |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JPH03261783A (ja) | 1990-03-12 | 1991-11-21 | Suntory Ltd | 1,2,4―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤 |
DE4030042A1 (de) | 1990-05-17 | 1991-11-21 | Bayer Ag | Verwendung von substituierten 1,2,4-triazindionen |
JP3018422B2 (ja) | 1990-07-27 | 2000-03-13 | 日東紡績株式会社 | 床 材 |
US5630962A (en) | 1990-12-19 | 1997-05-20 | Hoechst Aktiengesellschaft | 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures |
JPH0539272A (ja) | 1991-01-09 | 1993-02-19 | Nissan Chem Ind Ltd | ピリミジンジオン誘導体および除草剤 |
JPH0525142A (ja) | 1991-07-12 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
JPH05202031A (ja) | 1992-01-28 | 1993-08-10 | Nissan Chem Ind Ltd | N−アミノピリミジンジオン誘導体および除草剤 |
WO1993018016A1 (en) | 1992-03-11 | 1993-09-16 | E.I. Du Pont De Nemours And Company | Fungicidal oxazolidinones |
US5482951A (en) | 1992-05-29 | 1996-01-09 | Kumiai Chemical Industry Co., Ltd. | Triazole derivatives as well as insecticide and acaricide |
EP0612320A1 (en) | 1992-08-31 | 1994-08-31 | Ciba-Geigy Ag | 4,5-dicyanoimidazole derivatives and pesticidal compositions containing them |
AU673881B2 (en) | 1992-12-25 | 1996-11-28 | Nippon Soda Co., Ltd. | Heterocyclic derivative and pest control agent |
JP3261783B2 (ja) | 1993-02-04 | 2002-03-04 | ミノルタ株式会社 | 光変調素子 |
JP3682075B2 (ja) | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
WO1995004724A1 (fr) | 1993-08-11 | 1995-02-16 | Nippon Soda Co., Ltd. | Derive d'imidazole et son procede de production, et substance anti-nuisibles |
JPH0873446A (ja) | 1994-04-22 | 1996-03-19 | Nippon Soda Co Ltd | ヘテロ環化合物および殺虫・殺ダニ剤 |
JPH0827120A (ja) | 1994-07-08 | 1996-01-30 | Nissan Chem Ind Ltd | テトラヒドロピリミジノン誘導体 |
JPH08217777A (ja) | 1995-02-10 | 1996-08-27 | Nippon Nohyaku Co Ltd | 2−ピラゾリン−5−オン誘導体及びその中間体並びに除草剤 |
DE19518681A1 (de) | 1995-05-22 | 1996-11-28 | Bayer Ag | Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
JPH09291282A (ja) | 1996-04-26 | 1997-11-11 | Sumitomo Chem Co Ltd | 安定化した液晶材料およびこれを用いた液晶素子 |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6355799B1 (en) * | 1997-10-27 | 2002-03-12 | Isk Americas Incorporated | Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them |
US6521641B1 (en) | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
WO2000024735A1 (en) | 1998-10-23 | 2000-05-04 | Dow Agrosciences Llc | Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles |
GB9903671D0 (en) | 1999-02-17 | 1999-04-14 | Cenes Ltd | Dopamine D-1 receptor agonist compounds |
BR0107662A (pt) | 2000-01-18 | 2002-11-19 | Pfizer Prod Inc | Antagonistas do fator de liberação de corticotropina |
JP3831253B2 (ja) | 2000-04-04 | 2006-10-11 | 塩野義製薬株式会社 | 高脂溶性化合物を含有する油性組成物 |
CA2409762A1 (en) | 2000-06-23 | 2002-01-03 | Donald J.P. Pinto | Heteroaryl-phenyl substituted factor xa inhibitors |
US6476055B1 (en) | 2001-03-28 | 2002-11-05 | Nippon Soda Co. Ltd. | 5,5-disubstituted thiazolidine derivative pesticides |
US7501429B2 (en) | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
EP1386915A4 (en) | 2001-05-09 | 2004-11-10 | Sumitomo Chem Takeda Agro Co | AZOLE-LIKE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE OF SAID COMPOUNDS |
AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
ES2421511T3 (es) | 2001-12-21 | 2013-09-03 | X Ceptor Therapeutics Inc | Moduladores de LXR |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
WO2003079986A2 (en) | 2002-03-18 | 2003-10-02 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
WO2004018410A1 (ja) | 2002-08-26 | 2004-03-04 | Nissan Chemical Industries, Ltd. | 置換ベンズアニリド化合物及び有害生物防除剤 |
AU2003276201A1 (en) | 2002-11-11 | 2004-06-03 | Bayer Healthcare Ag | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist |
US20040171075A1 (en) | 2002-12-31 | 2004-09-02 | Flynn Daniel L | Modulation of protein functionalities |
CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
US6969744B2 (en) | 2003-06-19 | 2005-11-29 | University Of Southern Mississippi | Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation |
EA009201B1 (ru) | 2003-09-03 | 2007-12-28 | Пфайзер Инк. | Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2 |
JP4451849B2 (ja) | 2003-11-28 | 2010-04-14 | 日本曹達株式会社 | アリール複素環誘導体および農園芸用殺菌剤および殺虫剤 |
JP2005272452A (ja) | 2004-02-23 | 2005-10-06 | Nissan Chem Ind Ltd | 置換ベンズアニリド化合物及び有害生物防除剤 |
JP2007533723A (ja) | 2004-04-20 | 2007-11-22 | ファイザー・プロダクツ・インク | α2δリガンドを含む組合せ |
WO2005113494A2 (en) | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
TW200612827A (en) | 2004-08-25 | 2006-05-01 | Sumitomo Chemical Co | Insecticide composition |
ES2396365T3 (es) * | 2005-07-29 | 2013-02-21 | Concert Pharmaceuticals Inc. | Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina |
US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
GB0524786D0 (en) | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
CA2641766A1 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
JP5025142B2 (ja) | 2006-02-27 | 2012-09-12 | 株式会社東芝 | モータ制御装置 |
BRPI0708731A2 (pt) | 2006-03-10 | 2011-06-07 | Ono Pharmaceutical Co | derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
WO2007124546A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
PT2094663E (pt) | 2006-09-21 | 2011-04-19 | Piramal Life Sciences Ltd | Derivados de piridina para o tratamento de desordens metabólicas relacionadas com resistência à insulina ou hiperglicemia |
EP2256496A3 (en) | 2006-09-21 | 2011-03-16 | Piramal Life Sciences Limited | Method for identifying compounds that act as insulin-sensitizers |
RU2478635C2 (ru) | 2006-10-19 | 2013-04-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений |
EP1916240A1 (en) * | 2006-10-25 | 2008-04-30 | Syngeta Participations AG | Pyridazine derivatives |
DE102007003036A1 (de) | 2006-12-20 | 2008-06-26 | Bayer Cropscience Ag | Pyrimidinylpyrazole |
WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
JP2010519267A (ja) | 2007-02-22 | 2010-06-03 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 新規殺微生物剤 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
AR065622A1 (es) | 2007-03-07 | 2009-06-17 | Ortho Mcneil Janssen Pharm | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
CN101294257B (zh) | 2007-04-23 | 2014-06-18 | 株式会社神户制钢所 | 焊接热影响部的韧性优异的钢材及其制造方法 |
JP2009062290A (ja) | 2007-09-04 | 2009-03-26 | Takeda Chem Ind Ltd | シクロプロパン化合物 |
EA019085B1 (ru) * | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны |
EP2203426B9 (en) | 2007-10-31 | 2013-02-13 | Abbott GmbH & Co. KG | Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US20110071197A1 (en) | 2008-04-16 | 2011-03-24 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
US20110112193A1 (en) | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
CA2736970A1 (en) * | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivatives for use as medicaments |
WO2010064688A1 (ja) | 2008-12-03 | 2010-06-10 | 日本農薬株式会社 | ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法 |
WO2010068788A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
PE20142099A1 (es) | 2009-01-12 | 2014-12-13 | Icagen Inc | Derivados de sulfonamida |
EP2246335A1 (de) | 2009-02-17 | 2010-11-03 | Bayer CropScience AG | Aminopyrimidinamide als Schädlingsbekämpfungsmittel |
AU2011223888B2 (en) * | 2010-03-04 | 2015-07-02 | Merck Sharp & Dohme Llc | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
CA2812043A1 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Pyrimidinedione anti-viral compounds |
KR20120018236A (ko) | 2010-07-23 | 2012-03-02 | 현대약품 주식회사 | 치환된 피리미디닐 유도체 및 이의 제조방법 |
WO2012020848A1 (en) | 2010-08-10 | 2012-02-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
PL2753606T3 (pl) * | 2011-09-02 | 2018-02-28 | Purdue Pharma L.P. | Pirymidyny jako blokery kanałów sodowych |
EP3323821A1 (en) * | 2012-11-08 | 2018-05-23 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
GEP201606598B (en) * | 2012-11-08 | 2017-01-10 | Pfizer | Heteroaromatic compounds as dopamine d1 ligands |
WO2014119770A1 (ja) * | 2013-01-30 | 2014-08-07 | 住友化学株式会社 | ピリダジノン化合物及びそれを含有する除草剤 |
WO2014207601A1 (en) * | 2013-06-27 | 2014-12-31 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
-
2014
- 2014-06-13 WO PCT/IB2014/062217 patent/WO2014207601A1/en active Application Filing
- 2014-06-13 ES ES18180416T patent/ES2948192T3/es active Active
- 2014-06-13 MX MX2015017169A patent/MX2015017169A/es unknown
- 2014-06-13 MX MX2020013099A patent/MX2020013099A/es unknown
- 2014-06-13 JP JP2015563113A patent/JP6026024B2/ja active Active
- 2014-06-13 SG SG11201509186TA patent/SG11201509186TA/en unknown
- 2014-06-13 PL PL18180416.2T patent/PL3421462T3/pl unknown
- 2014-06-13 CU CUP2015000180A patent/CU24334B1/es unknown
- 2014-06-13 CN CN201480036014.7A patent/CN105324376B/zh active Active
- 2014-06-13 AP AP2015008844A patent/AP2015008844A0/xx unknown
- 2014-06-13 HR HRP20230546TT patent/HRP20230546T1/hr unknown
- 2014-06-13 DK DK18180416.2T patent/DK3421462T3/da active
- 2014-06-13 RS RS20230446A patent/RS64342B1/sr unknown
- 2014-06-13 PT PT181804162T patent/PT3421462T/pt unknown
- 2014-06-13 AU AU2014300673A patent/AU2014300673B2/en active Active
- 2014-06-13 FI FIEP18180416.2T patent/FI3421462T3/fi active
- 2014-06-13 NZ NZ713762A patent/NZ713762A/en not_active IP Right Cessation
- 2014-06-13 HU HUE18180416A patent/HUE062265T2/hu unknown
- 2014-06-13 UA UAA201510712A patent/UA112945C2/uk unknown
- 2014-06-13 PE PE2015002614A patent/PE20160664A1/es unknown
- 2014-06-13 EP EP18180416.2A patent/EP3421462B1/en active Active
- 2014-06-13 ES ES14739554T patent/ES2729630T3/es active Active
- 2014-06-13 KR KR1020157036343A patent/KR101781723B1/ko active IP Right Grant
- 2014-06-13 CA CA2916653A patent/CA2916653C/en active Active
- 2014-06-13 PL PL14739554T patent/PL3013813T3/pl unknown
- 2014-06-13 RS RS20190843A patent/RS59018B1/sr unknown
- 2014-06-13 MA MA38661A patent/MA38661A1/fr unknown
- 2014-06-13 TR TR2019/07981T patent/TR201907981T4/tr unknown
- 2014-06-13 MD MDA20150122A patent/MD20150122A2/ro not_active Application Discontinuation
- 2014-06-13 EA EA201592146A patent/EA028637B1/ru unknown
- 2014-06-13 DK DK14739554.5T patent/DK3013813T3/da active
- 2014-06-13 TN TN2015000547A patent/TN2015000547A1/fr unknown
- 2014-06-13 EP EP14739554.5A patent/EP3013813B1/en active Active
- 2014-06-13 BR BR122023004130-5A patent/BR122023004130B1/pt active IP Right Grant
- 2014-06-13 HU HUE14739554A patent/HUE043705T2/hu unknown
- 2014-06-13 PT PT14739554T patent/PT3013813T/pt unknown
- 2014-06-23 US US14/311,963 patent/US9527831B2/en active Active
- 2014-06-24 TW TW103121727A patent/TWI508957B/zh active
- 2014-06-26 AR ARP140102420A patent/AR096748A1/es unknown
- 2014-06-26 UY UY0001035628A patent/UY35628A/es not_active Application Discontinuation
-
2015
- 2015-03-04 US US14/638,677 patent/US9107923B2/en active Active
- 2015-03-04 US US14/638,608 patent/US9139561B2/en active Active
- 2015-10-30 PH PH12015502502A patent/PH12015502502A1/en unknown
- 2015-11-05 IL IL242480A patent/IL242480B/en active IP Right Grant
- 2015-11-09 ZA ZA2015/08252A patent/ZA201508252B/en unknown
- 2015-12-03 CR CR20150634A patent/CR20150634A/es unknown
- 2015-12-18 DO DO2015000302A patent/DOP2015000302A/es unknown
- 2015-12-22 NI NI201500179A patent/NI201500179A/es unknown
- 2015-12-22 GT GT201500350A patent/GT201500350A/es unknown
- 2015-12-24 CL CL2015003735A patent/CL2015003735A1/es unknown
-
2016
- 2016-01-22 EC ECIEPI20163103A patent/ECSP16003103A/es unknown
- 2016-03-23 HK HK16103425.1A patent/HK1215435A1/zh unknown
- 2016-11-11 US US15/349,075 patent/US9822097B2/en active Active
-
2017
- 2017-10-10 US US15/729,111 patent/US10093655B2/en active Active
-
2018
- 2018-09-06 US US16/123,072 patent/US10421744B2/en active Active
-
2019
- 2019-06-27 HR HRP20191163TT patent/HRP20191163T1/hr unknown
- 2019-08-13 US US16/539,865 patent/US10696658B2/en active Active
-
2020
- 2020-05-21 US US16/880,632 patent/US11014909B2/en active Active
-
2021
- 2021-03-17 US US17/204,095 patent/US11964961B2/en active Active
-
2024
- 2024-03-18 US US18/607,834 patent/US20240317713A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201500179A (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
NI201500066A (es) | ||
AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
CL2012001397A1 (es) | Compuestos hetero-triciclicos condensados, moduladores de quinasa jak; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la prepararcion de medicamentos utiles en el tratamiento de enfermedades autoinmunes, cancer y trastornos del sistema nervioso central, entre otras. | |
CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
ECSP099823A (es) | Nuevos compuestos químicos | |
AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
ECSP11010786A (es) | 5-alquinil-pirimidinas | |
NI201600160A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
NI201600161A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
PH12019500119A1 (en) | Ethynyl derivatives | |
AR100532A1 (es) | Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona | |
CO6592046A2 (es) | 5-alquinil pirimidas y su uso como inhibidores de quinasa | |
EA201992108A1 (ru) | Ингибиторы бета-секретазы | |
CL2009000118A1 (es) | Compuestos derivados de carboxamida o carboxatioamida azabiciclica, moduladores de trv1; composicion farmaceutica que los contiene; proceso de preparacion de los compuestos e intermediarios; y uso en el tratamiento del dolor, inflamacion, trastornos metabolico, entre otras. | |
MX2016001528A (es) | Derivados de indol-carboxamida. | |
TH167754A (th) | ไพเพอราซิโน[1,2-a]อินดอล-1-โอนและ[1,4]ไดอะซีพิโน[1,2-a]อินดอล-1-โอน |